Skip to main content
VMD logo

VMD · Viemed Healthcare, Inc.

Track VMD — free
$8.55 -0.06 (-0.70%)
Market Cap
$326.26M
Shares
37.89M
Volume · Nov 20 120.45K Avg daily vol (3M) 262.84K

Price & Indicators

 

Key stats

Close
$8.61
Thu 19 Nov
Open
$8.80
Thu 19 Nov
Average volume, 30 days
204K
shares a session
Short interest
1.5M
4.0% of shares · 8.5 days to cover
Day range
$8.54$8.86
Open $8.80 Close $8.61
52-week closing range
$6.26$12.33
Close $8.61 30.2% under the high
Short volume, last session
32%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 4
Price history
Jan 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 5
Earnings call
Record revenue drives higher earnings and raised guidance

ViMed reported record third-quarter revenue of $80.7 million and net income of $4.6 million, raised full-year revenue guidance to $316 million to $320 million, and plans maternal health expansion at two states per quarter.

4 source passages
The third quarter was another strong quarter for ViMed, with a record revenue of $80.7 million, representing 12.2% growth over last year. Net income attributable to BiMed was $4.6 million, or 11 cents per diluted share, compared with $3.5 million, or 9 cents per diluted share a year ago, and $2.8 million, or 7 cents per diluted share in the second quarter of this year. We are raising the lower end of our full-year revenue guidance and now expect revenue of $316 million to $320 million, compared with our previous range of $314 to $320 million. We are now on track to enter two additional states per quarter, beginning in the fourth quarter, establishing a regular pace of expansion. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly revenue rises 12.2%, net income rises 31.6%

Viemed Healthcare reported quarterly revenue of $80.7 million, up 12.2%, and net income of $4.7 million, up 31.6%, for the three months ended September 30, 2026.

Revenue $80.67M ▲ 12.2% Net income $4.64M ▲ 32.0% Diluted EPS $0.11 ▲ 22.2%
Read from the MD&A section
3 source passages
In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and its subsidiaries in which it has a controlling financial interest. For the three months ended September 30, 2026, total revenue was $80.7 million, an increase of $8.8 million, or 12.2%, compared to the three months ended September 30, 2025. For the three months ended September 30, 2026, net income was $4.7 million, an increase of $1.1 million, or 31.6% from the comparable period in 2025. Open the document at this passage
Nov 4
Current report 8-K
Record revenue drives stronger profit and tighter guidance

Viemed Healthcare reported record third-quarter net revenue of $80.7 million, up 12.2% year over year, and raised full-year revenue guidance to $316 million to $320 million while narrowing Adjusted EBITDA guidance to $64 million to $66 million.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three and nine months ended September 30, 2026, and updated guidance for the full year ending December 31, 2026. Net revenue for the quarter ended September 30, 2026 totaled a Company record $80.7 million, an increase of $8.8 million, or 12.2%, compared with the prior-year quarter, and 3.3% sequentially. Net revenue is expected to be in the range of $316 million to $320 million, compared with the previous range of $314 million to $320 million. Adjusted EBITDA is expected to range from $64 million to $66 million, compared with the previous range of $64 million to $68 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$310.37M
Trailing 12 months
Net income (TTM)
$15.45M
Trailing 12 months
Revenue growth YoY
+12.2%
Year over year
Operating margin
7.8%
Trailing 12 months
P / E (TTM)
22.7
Trailing earnings · reciprocal yield 4.4%
FCF yield
6.6%
TTM · current market cap
Return on invested capital
11.7%
Trailing 12 months
Net cash
$4.66M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
+37.5%
Trailing year
Short interest
4.0%
Latest settlement · 8.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. ViMed delivered record revenue, stronger sequential earnings, expanding sleep volumes, ventilation revenue growth, and a planned maternal health rollout; it also raised the revenue guidance floor and lowered its capital-expenditure outlook while reducing debt and repurchasing shares. Offsetting these gains were lower gross and year-over-year Adjusted EBITDA margins, reduced cash conversion and higher audit costs, softer period-end ventilation patients, a lower Adjusted EBITDA guidance ceiling, and time needed for maternal health markets to mature.

Bullish
  • + PAP therapy and sleep resupply patient volumes grew strongly year over year and sequentially.
  • + Ventilator rental revenue increased 7.4% year over year and 2.9% sequentially to $37.5 million, supported by higher average patient volumes. new
  • + The maternal health rollout is expected to expand at a cadence of two additional states per quarter beginning in the fourth quarter. new
  • + ViMed reduced debt and returned capital through share repurchases during the quarter. new
Bearish
  • − Gross margin declined year over year and sequentially as sales and services increased to 32% of revenue. new
  • − Adjusted EBITDA margin was 21.1%, below 22.4% a year earlier. new
  • − Industry audit activity is increasing administrative and professional costs and can extend payment timelines. new
  • − The period-end ventilator patient count declined sequentially, and management described patient-count trends as wobbly. new
  • − The upper end of full-year Adjusted EBITDA guidance was lowered.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −7%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 39%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −13%
trailing
6-month return −11%
trailing
YTD return +16%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.98% of shares out · ▼ -1.7% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
169 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Excellent
Revenue growth +21%
Y/Y
Gross margin 58%
contracting
EPS growth +32%
Y/Y
Free cash flow $11.9M
Valuation P/E 22.7
below peers
Balance sheet $1.1M
net cash
Quant / Vol
risk profile
Moderate
Volatility 41%
annualized · 1-yr
Max drawdown −30%
past year
ATR 3.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the Earnings Call filed Nov 5, 2026
Revenue · full-year Maintained $316M – $320M
Nov 4, 2026 $316M – $320M changed to Nov 5, 2026 $316M – $320M
prior FY $270.28M midpoint +17.7% Y/Y
Adjusted EBITDA · full-year Non-GAAP Maintained $64M – $66M
Nov 4, 2026 $64M – $66M changed to Nov 5, 2026 $64M – $66M
Net capex outlook, as a percentage of revenue · full-year Lowered 8% – 9%
Aug 4, 2026 8.5% – 10% changed to Nov 5, 2026 8% – 9%
Previous outlook earlier release · from the 8-K filed Nov 4, 2026

Still-open targets the latest release did not restate under the same label.

Net capital expenditures as a percentage of net revenue · full year ending December 31, 2026 8% – 9%
Guided vs delivered · last 8 settled
Net Revenue year ending December 31, 2025
guided $271M – $273M
$270.28M Miss −0.6%
Net revenues the third quarter of 2024
guided $56.5M – $57.7M
$58M Beat +1.6%
Net revenues second quarter of 2024
guided $53.8M – $54.8M
$54.97M Beat +1.2%
Net revenues first quarter of 2024
guided $49.7M – $51M
$50.59M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
39% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.98% of shares out · ▼ -1.7% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
169 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $9 · 39% Range high $12
vs 200-day avg -11% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Average buyback price per share $9.65 the second quarter of 2026 —
Free cash flow non-GAAP 34.4M the trailing twelve months ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities 60.78M
-31.55M Purchase of property and equipment
+5.2M Proceeds from sale of property and equipment
= Free cash flow 34.43M
Net cash provided by operating activities 60.8M the trailing twelve months ended June 30, 2026 —
Shares repurchased and cancelled 530,802 the second quarter of 2026 —
Total number of shares (or units) purchased 535,260 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VMD
Viemed Healthcare, Inc.
this stock
$326.26M +15.9% +20.5% 22.7 4.0%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
169
% held
71.9%
Net QoQ
+1.7M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
153
View
Short & Settlement
Short Interest Falling
Shares short
1.5M
Days to cover
8.5d
Change
-25.9K sh
View
Short Volume
Short vol %
32%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
544
Value
$5.3K
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
33.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$270.3M
Net income (FY)
$14.9M
EPS diluted
$0.37
View
Buybacks
Authorized
shares 1.9M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
15

Viemed Healthcare reported quarterly revenue of $80.7 million, up 12.2%, and net income of $4.7 million, up 31.6%, for the three months ended September 30, 2026.

View
Proposed Sales
Value
$570.1K
Shares
65.0K
Filed
Mar 20, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Viemed Healthcare Announces Third…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
VMD -5.5% -13.2% -11.4% -11.0% +15.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY 0.0% -6.9% -5.8% -5.7% +10.9%

Capital returns

Buyback program · as of Mar 4, 2026
Authorized
shares 1.93M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1729149 CUSIP 92663R105 13F (30d) 168 filings 151 filers Visit website Investor relations